{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T03:42:17Z","timestamp":1787024537913,"version":"build-2736575974"},"reference-count":24,"publisher":"Japanese Society of Internal Medicine","issue":"13","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2024,7,1]]},"DOI":"10.2169\/internalmedicine.2501-23","type":"journal-article","created":{"date-parts":[[2023,11,5]],"date-time":"2023-11-05T17:12:38Z","timestamp":1699204358000},"page":"1855-1861","source":"Crossref","is-referenced-by-count":7,"title":["The Comparison between Vadadustat and Daprodustat Regarding Dose, Cost, and Safety of Treatment for Renal Anemia in Non-dialysis Patients with Chronic Kidney Diseases"],"prefix":"10.2169","volume":"63","author":[{"given":"Enyu","family":"Imai","sequence":"first","affiliation":[{"name":"Nakayamadera Imai Clinic, Japan"},{"name":"Fujita Health University School of Medicine, Japan"},{"name":"Aichi Medical University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsuhiro","family":"Imai","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Osaka University Graduate School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Silverberg DS, Wexler D, Iaina A, Steinbruch S, Wollman Y, Schwartz D. Anemia, chronic renal disease and congestive heart failure - the cardio renal anemia syndrome: the need for cooperation between cardiologists and nephrologists. Int Urol Nephrol 38: 295-310, 2006.","DOI":"10.1007\/s11255-006-0064-8"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Macdougall IC, Lewis NP, Saunders MJ, et al. Long-term cardiorespiratory effects of amelioration of renal anaemia by erythropoietin. Lancet 335: 489-493, 1990.","DOI":"10.1016\/0140-6736(90)90733-L"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Sugahara M, Tanaka T, Nangaku M. Future perspectives of anemia management in chronic kidney disease using hypoxia-inducible factor-prolyl hydroxylase inhibitors. Pharmacol Ther 239: 108272, 2022.","DOI":"10.1016\/j.pharmthera.2022.108272"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Locatelli F, Del Vecchio L. Hypoxia-inducible factor-prolyl hydroxyl domain inhibitors: from theoretical superiority to clinical noninferiority compared with current ESAs? J Am Soc Nephrol 33: 1966-1979, 2022.","DOI":"10.1681\/ASN.2022040413"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Provenzano R, Szczech L, Leong R, et al. Efficacy and cardiovascular safety of roxadustat for treatment of anemia in patients with non-dialysis-dependent CKD: pooled results of three randomized clinical trials. Clin J Am Soc Nephrol 16: 1190-1200, 2021.","DOI":"10.2215\/CJN.16191020"},{"key":"#cr-split#-6.1","unstructured":"6. US Food and Drug Administration. Roxadustat for the treatment of anemia due to chronic kidney disease in adult patients not on dialysis and on dialysis. FDA Presentation: Cardiovascular and Renal Drugs Advisory Committee Meeting [Internet]. [updated 2021 Jul 15"},{"key":"#cr-split#-6.2","unstructured":"cited 2023 May 27]. Available from: https:\/\/www.fda.gov\/media\/150756\/download"},{"key":"#cr-split#-7.1","unstructured":"7. Akebia Therapeutics. Press release. Akebia therapeutics receives complete response letter from the FDA for vadadustat for the treatment of anemia due to chronic kidney disease in adult patients [Internet]. [updated 2022 Mar 30"},{"key":"#cr-split#-7.2","unstructured":"cited 2023 May 27]. Available from: https:\/\/ir.akebia.com\/news-releases\/news-release-details\/akebia-therapeutics-receives-complete-response-letter-fda"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Chertow GM, Pergola PE, Farag YMK, et al. Vadadustat in patients with anemia and non-dialysis-dependent CKD. N Engl J Med 384: 1589-1600, 2021.","DOI":"10.1056\/NEJMoa2035938"},{"key":"#cr-split#-9.1","unstructured":"9. U.S. Food and Drug Administration. Updated contact information: October 26, 2022 meeting of the Cardiovascular and Renal Drugs Advisory Committee meeting announcement [Internet]. [updated 2022 Oct 26"},{"key":"#cr-split#-9.2","unstructured":"cited 2023 May 31]. Available from: https:\/\/www.fda.gov\/advisory-committees\/advisory-committee-calendar\/updated-contact-information-october-26-2022-meeting-cardiovascular-and-renal-drugs-advisory."},{"key":"10","unstructured":"10. Japanese Society of Nephrology. The Guideline for the Diagnosis and Treatment of Chronic Kidney Disease 2018. Tokyo Igakusha, Tokyo, 2018."},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Nangaku M, Kondo K, Kokado Y, et al. Phase 3 randomized study comparing vadadustat with darbepoetin alfa for anemia in Japanese patients with nondialysis-dependent CKD. J Am Soc Nephrol 32: 1779-1790, 2021.","DOI":"10.1681\/ASN.2020091311"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Singh AK, Carroll K, McMurray JJV, et al. Daprodustat for the treatment of anemia in patients not undergoing dialysis. N Engl J Med 385: 2313-2324, 2021.","DOI":"10.1056\/NEJMoa2113380"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Nangaku M, Hamano T, Akizawa T, et al. Daprodustat compared with epoetin beta pegol for anemia in Japanese patients not on dialysis: a 52-week randomized open-label phase 3 trial. Am J Nephrol 52: 26-35, 2021.","DOI":"10.1159\/000513103"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Pergola PE, Spinowitz BS, Hartman CS, Maroni BJ, Haase VH. Vadadustat, a novel oral HIF stabilizer, provides effective anemia treatment in nondialysis-dependent chronic kidney disease. Kidney Int 90: 1115-1122, 2016.","DOI":"10.1016\/j.kint.2016.07.019"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Haase VH. HIF-prolyl hydroxylases as therapeutic targets in erythropoiesis and iron metabolism. Hemodial Int 21: S110-S124, 2017.","DOI":"10.1111\/hdi.12567"},{"key":"16","unstructured":"16. Japanese Society of Nephrology. The guideline for the diagnosis and treatment of chronic kidney disease. Tokyo Igakusya, Tokyo, 2023."},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Mohamed MMG, Oyenuga M, Shaikh S, Oyenuga A, Kheiri B, Nwankwo C. Hypoxia inducible factorprolyl hydroxylase inhibitors in anemic patients with non-dialysis dependent chronic kidney disease: a meta-analysis of randomized clinical trials. Int Urol Nephrol 55: 167-171, 2023.","DOI":"10.1007\/s11255-022-03300-7"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Singh AK, Causland FRM, Claggett BL, et al. Analysis of on-treatment cancer safety events with daprodustat versus conventional erythropoiesis-stimulating agents - post hoc analyses of the ASCEND-ND and ASCEND-D trials. Nephrol Dial Transplant 38: 1890-1897, 2022.","DOI":"10.1093\/ndt\/gfac342"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Fatima K, Ahmed W, Fatimi AS, et al. Evaluating the safety and efficacy of daprodustat for anemia of chronic kidney disease: a meta-analysis of randomized clinical trials. Eur J Clin Pharmacol 78: 1867-1875, 2022.","DOI":"10.1007\/s00228-022-03395-y"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Nangaku M, Akizawa T, Nagakubo T, et al. Safety of daprodustat in patients with anemia of chronic kidney disease: a pooled analysis of phase 3 studies in Japan. Ther Apher Dial 26: 1065-1078, 2022.","DOI":"10.1111\/1744-9987.13839"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Tanaka K, Watanabe T, Takeuchi A, et al; CKD-JAC Investigators. Cardiovascular events and death in Japanese patients with chronic kidney disease. Kidney Int 91: 227-234, 2017.","DOI":"10.1016\/j.kint.2016.09.015"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/63\/13\/63_2501-23\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,5]],"date-time":"2024-07-05T23:29:05Z","timestamp":1720222145000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/63\/13\/63_2501-23\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,1]]},"references-count":24,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.2501-23","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,1]]},"article-number":"2501-23"}}